Viking Therapeutics, Inc. (NASDAQ:VKTX)‘s stock had its “buy” rating reissued by stock analysts at Maxim Group in a research report issued on Wednesday. They presently have a $5.00 price objective on the biotechnology company’s stock. Maxim Group’s price target suggests a potential upside of 164.55% from the stock’s current price.

Several other equities research analysts have also commented on VKTX. HC Wainwright reissued a “buy” rating and set a $7.00 price objective (up previously from $5.00) on shares of Viking Therapeutics in a research note on Monday, July 17th. ValuEngine lowered shares of Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, July 28th.

Shares of Viking Therapeutics (NASDAQ:VKTX) traded up 0.53% during trading on Wednesday, reaching $1.90. 352,469 shares of the company traded hands. The stock’s market capitalization is $52.62 million. Viking Therapeutics has a 12-month low of $0.90 and a 12-month high of $2.01. The firm’s 50 day moving average is $1.45 and its 200-day moving average is $1.45.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.02). On average, equities research analysts anticipate that Viking Therapeutics will post ($0.82) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Viking Therapeutics, Inc. (VKTX) Given “Buy” Rating at Maxim Group” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at

A number of large investors have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in shares of Viking Therapeutics by 62.9% in the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock worth $388,000 after buying an additional 102,600 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in shares of Viking Therapeutics in the second quarter worth approximately $124,000. Finally, Sabby Management LLC bought a new position in shares of Viking Therapeutics in the second quarter worth approximately $525,000. 5.67% of the stock is currently owned by institutional investors and hedge funds.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with's FREE daily email newsletter.